Cerus Corporation

CERS | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.62

+$0.06 (+2.34%)

Sep 22, 2026, 1:59 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.34%

(1D)

Rating

Updated: Aug 28, 2026

36.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $526.99M

1D Range

2.52 2.67

52W Range

1.38 3.47

Valuation (TTM)

PE -81.27

PB 7.30

EV/EBITDA 202.51

Valuation (NTM)

Forward PE 256.00

Forward PEG 0.98

Price Target $4

Cash Flow

FCF Yield -0.3%

SBC Adj. FCF Yield -4.4%

SBC Impact -1145.5%

Margins

Gross Margin 52.0%

Operating Margin -3.7%

FCF Margin -0.8%

Growth (CAGR)

Revenue 3Y | 5Y 14.1% | 16.4%

Dil EPS 3Y | 5Y 56.5% | 38.3%

FCF 3Y | 5Y 148.6% | 52.9%

Returns

ROA -3.3%

ROE -10.3%

ROIC -1.1%

Financial Health

Net Cash

$14.29M

Current Ratio 1.83

Interest Coverage -0.21

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood ...

Sector Healthcare

Industry Medical - Devices

Employees 268

IPO Date Jan 30, 1997

Website www.cerus.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+52.67%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞